TECTONIC THERAPEUTIC INC (TECX) Stock Price, Forecast & Analysis
NASDAQ:TECX • US8789721086
TECX Key Statistics, Chart & Performance
The current stock price of TECX is 22.71 USD. In the past month the price increased by 15.46%. In the past year, price decreased by -36.15%.
TECX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to TECX. When comparing the yearly performance of all stocks, TECX is a bad performer in the overall market: 74.63% of all stocks are doing better.
TECX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TECX. TECX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TECX Financial Highlights
Over the last trailing twelve months TECX reported a non-GAAP Earnings per Share(EPS) of -3.86. The EPS increased by 60.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.3% | ||
| ROE | -25.16% | ||
| Debt/Equity | 0 |
TECX Forecast & Estimates
15 analysts have analysed TECX and the average price target is 81.47 USD. This implies a price increase of 258.75% is expected in the next year compared to the current price of 22.71.
TECX Ownership
TECX Latest News, Press Relases and Analysis
TECX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TECX
Company Profile
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Company Info
TECTONIC THERAPEUTIC INC
490 Arsenal Way, Suite 210
Watertown MASSACHUSETTS US
Employees: 51
Phone: 13396663320
TECTONIC THERAPEUTIC INC / TECX FAQ
What does TECX do?
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Can you provide the latest stock price for TECTONIC THERAPEUTIC INC?
The current stock price of TECX is 22.71 USD. The price increased by 3.18% in the last trading session.
Does TECTONIC THERAPEUTIC INC pay dividends?
TECX does not pay a dividend.
How is the ChartMill rating for TECTONIC THERAPEUTIC INC?
TECX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is TECX stock listed?
TECX stock is listed on the Nasdaq exchange.
What is the market capitalization of TECX stock?
TECTONIC THERAPEUTIC INC (TECX) has a market capitalization of 425.13M USD. This makes TECX a Small Cap stock.
When does TECTONIC THERAPEUTIC INC (TECX) report earnings?
TECTONIC THERAPEUTIC INC (TECX) will report earnings on 2026-03-18, after the market close.